search
Back to results

Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes. (EGOFIP)

Primary Purpose

Type 2 Diabetes, Microvascular Dysfunction

Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Victoza
Sponsored by
Bispebjerg Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring diabetes, GLP-1, Victoza, CFR, microvascular dysfunction

Eligibility Criteria

25 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea.
  • Age: 25-75 years
  • BMI>25 kg/m2
  • HbA1c 6,0-10 %

Exclusion Criteria:

  • Current treatment with insulin or Dipeptidyl peptidase IV inhibitor.
  • Haemoglobin < 6.5 mmol/l
  • Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study.
  • Allergy towards victoza ® (liraglutide ), Dipyridamol, Nitroglycerin or rescue medicine: Theophyllin
  • Pregnancy
  • Severe asthma
  • Active cancer
  • Severe co-morbidity with limited life-expectancy
  • Estimated glomerular filtration rate (eGFR) <60 (measured at baseline)
  • Severe hepatic co-morbidity
  • Chronic alcohol abuse
  • Heart failure with a left ventricular ejection fraction </= 45%
  • Atrial fibrillation
  • Chronic or previous acute pancreatitis
  • Inflammatory bowel disease.

Sites / Locations

  • Bispebjerg Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

victoza

No treatment

Arm Description

The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment

Outcomes

Primary Outcome Measures

Change in coronary flow reserve (CFR)
CFR can be reliably assessed non-invasively by trans-thoracic Doppler flow echocardiography of the left anterior descending artery with a success rate of over 90% even in an obese population with a relative poor acoustic window. CFR is the ratio of flow during stress to during rest.

Secondary Outcome Measures

Change in Endothelial function:
Measurement of Peripheral Arterial Tone, with the use of the commercially available machine (Endo-PAT2000®) assesses the control of digital vascular tone by the sympathetic nervous system and nitric oxide (NO).

Full Information

First Posted
August 20, 2013
Last Updated
June 24, 2014
Sponsor
Bispebjerg Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01931982
Brief Title
Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.
Acronym
EGOFIP
Official Title
Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
May 2013 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Bispebjerg Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Microvascular Dysfunction
Keywords
diabetes, GLP-1, Victoza, CFR, microvascular dysfunction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
victoza
Arm Type
Active Comparator
Arm Description
The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment
Arm Title
No treatment
Arm Type
No Intervention
Intervention Type
Drug
Intervention Name(s)
Victoza
Primary Outcome Measure Information:
Title
Change in coronary flow reserve (CFR)
Description
CFR can be reliably assessed non-invasively by trans-thoracic Doppler flow echocardiography of the left anterior descending artery with a success rate of over 90% even in an obese population with a relative poor acoustic window. CFR is the ratio of flow during stress to during rest.
Time Frame
CFR is measured at baseline and after 10 weeks of intervention
Secondary Outcome Measure Information:
Title
Change in Endothelial function:
Description
Measurement of Peripheral Arterial Tone, with the use of the commercially available machine (Endo-PAT2000®) assesses the control of digital vascular tone by the sympathetic nervous system and nitric oxide (NO).
Time Frame
Endothelial function is measured at baseline and after 10 weeks of intervention
Other Pre-specified Outcome Measures:
Title
Changes in HbA1c
Time Frame
Measurements at baseline and after 10 weeks of intervention
Title
Change in fasting C-peptide
Time Frame
C-peptide is measured at baseline and after 10 weeks of intervention
Title
Change in fasting insulin
Time Frame
Fasting insulin is measured at baseline and after 10 weeks of intervention
Title
Change in fasting glucose
Time Frame
Fasting glucose is measured at baseline and after 10 weeks of intervention
Title
Change in weight
Time Frame
Weight is measured at baseline and after 10 weeks of intervention
Title
Change in waist circumference
Time Frame
Waist circumference is measured at baseline and after 10 weeks of intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes on monotherapy with metformin or sulfonylurea or combination therapy of metformin and sulfonylurea. Age: 25-75 years BMI>25 kg/m2 HbA1c 6,0-10 % Exclusion Criteria: Current treatment with insulin or Dipeptidyl peptidase IV inhibitor. Haemoglobin < 6.5 mmol/l Documented significant stenosis of the left anterior descending artery (LAD) at coronary angiography or CT-angiography or regional dysfunction documented during dipyridamol stress-echocardiography. If stress test at baseline shows significant stenosis the patient will be excluded from the study. Allergy towards victoza ® (liraglutide ), Dipyridamol, Nitroglycerin or rescue medicine: Theophyllin Pregnancy Severe asthma Active cancer Severe co-morbidity with limited life-expectancy Estimated glomerular filtration rate (eGFR) <60 (measured at baseline) Severe hepatic co-morbidity Chronic alcohol abuse Heart failure with a left ventricular ejection fraction </= 45% Atrial fibrillation Chronic or previous acute pancreatitis Inflammatory bowel disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mette Zander, consultant
Organizational Affiliation
Department of Endocrinology, Bispebjerg Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bispebjerg Hospital
City
Copenhagen
State/Province
Capital region
ZIP/Postal Code
2400
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
25896352
Citation
Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study. Cardiovasc Diabetol. 2015 Apr 22;14:41. doi: 10.1186/s12933-015-0206-3.
Results Reference
derived

Learn more about this trial

Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.

We'll reach out to this number within 24 hrs